



**PRESS RELEASE (Int)**

**October 16, 2009**

**Britain's fastest-growing CRO,  
ClinTec International, expands MENA operation  
with launch of new Cairo office**

- *British firm at forefront of efforts to open up pharma and biotech sectors in the Middle East and North Africa region*
- *Egyptian presence provides global pharma firms with access to our unrivalled knowledge of regional regulatory requirements, understanding of local cultures, says ClinTec President and CEO Dr Rabinder Buttar*

ClinTec International, one of Britain's leading global clinical research organisations (CROs), has launched its Cairo office. The new operation will not only provide ClinTec International's global biopharmaceutical associates with access to new patient populations, but it also further consolidates the privately-owned British company's reputation as a major presence in the Middle East and North Africa (MENA) region.

"The launch of the new office cements ClinTec International's reputation as one of the few truly global providers of quality assured clinical research services," said ClinTec International Egypt Country Manager, Dalia Younan. "It also reflects the growing importance of Egypt – and wider MENA region – to the global clinical research market too."

With a presence in almost 40 countries around the world, including India (Bangalore) and Dubai (UAE), UK-headquartered ClinTec International manages clinical trials in all major therapeutic areas, including oncology, neurology, cardiovascular, respiratory as well as gastroenterology. It also has a wealth of experience in providing consultancy services in all aspects of quality assurance (QA), with ClinTec's QA team having all held senior positions within quality and manufacturing operations in the pharmaceutical, biotechnology and medical devices industries.

"With major international pharma firms now outsourcing clinical trials activities to new and emerging markets, quality assurance expertise has become increasingly vital to ensure all trials-related processes are independently verified," said Gráinne Forrest, ClinTec International's Head of Quality Assurance who was in Cairo for the official launch this week.

"Any expansion of Egypt's promising pharmaceuticals sector will, however, also draw attention to the need for internationally acceptable regulatory standards. ClinTec International's highly experienced QA personnel are now ready to share expertise with our new Egyptian colleagues," added Ms. Forrest.

"Our Cairo office launch received overwhelming support from medical directors from all the major pharmaceutical firms represented in the



region," said Dr Buttar. "Our unrivalled local expertise, including our knowledge of regional regulatory requirements and cultures, is our strength and it means the major pharmaceutical firms know they can always turn to us wherever in the world we operate – and indeed wherever in the world they want to operate, too.

"While North America and the European Union constitute the bulk of pharmaceutical sales and clinical research development, Egypt and the wider MENA region are growing at a phenomenal pace and are estimated to be worth some US\$10bn (£6.6bn) currently," added Dr Buttar. "At ClinTec we are proud to be at the forefront of opening up new and emerging markets and are delighted now to be helping to develop crucial expertise in Egypt and beyond."

**- ENDS -**

### **Notes to Editors**

#### **About ClinTec International**

ClinTec International is a global contract clinical research organisation, which was established in 1997 by Dr Rabinder Buttar, the company's President and CEO. ClinTec International has a presence in almost 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.

In addition to ClinTec International's vast expertise in oncology, the organisation has also conducted over 150 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International's 'fast, flexible and focused' approach to clinical research ensures an added advantage to the drug development process. The organisation's range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.

#### **ClinTec Media:**

Egypt contact: Ms Dalia Younan +2 010 0711702

Or ClinTec International's media team at:

John Macgill or Andrew Ritchie: + 44 (0) 131 556 0050 (including out of hours).

Website: [www.clintec.com](http://www.clintec.com)